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Background: Respiratory syncytial virus (RSV) is the leading cause of severe lower respiratory 
tract infections among infants and young children, and is responsible for an estimated four million 
deaths per year globally. A monthly injection of palivizumab has been used for prophylaxis 
of serious RSV infections among high-risk children in 71 countries since 1998 and approval 
for use in the Russian Federation was obtained in February 2010. A recommendation for RSV 
prophylaxis in the Russian Federation would require knowledge of the prevalence and seasonality 
of RSV in that country.
Methods: In a prospective, multicenter, epidemiological study of the prevalence, seasonality, and 
peak occurrence of RSV infection, children aged #2 years hospitalized for lower respiratory tract 
infections in three regions of the Russian Federation, from September 2008 through April 2009, 
were screened and tested for RSV using rapid immunochromatography of nasopharyngeal lavage. 
For subjects who were tested positive, hospitalization data were collected.
Results: Of 519 children aged #2 years enrolled from September 11, 2008 through April 26, 
2009, 197 tested positive for RSV (38.0%, 95% CI: 33.8, 42.3). The onset of the 2008–2009 
RSV season in the Russian Federation occurred in late October 2008, similar to what is observed 
in other northern temperate zones. Peak activity occurred in early April 2009, when 62% of 
children enrolled tested positive for RSV .
Conclusion: The prevalence of serious RSV infections in the Russian Federation is similar 
to the prevalence previously identified in other temperate zones of the northern hemisphere. 
The seasonality of disease shifted towards early spring, with peak activity later in the season, 
within a range reported in other countries. These data provide further evidence of serious RSV 
infection in children in the Russian Federation, as well as guidance for timing of seasonal RSV 
prophylaxis, especially among individuals at high risk for serious RSV infection.
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Introduction
Respiratory syncytial virus (RSV) is currently considered the single most important 
cause of childhood respiratory infection.1,2 The World Health Organization reports 
four million deaths annually worldwide among children aged ,5 years due to the 
virus.3 The primary cause of severe lower respiratory tract infection (LRTI) globally 
among infants aged ,2 years, the virus is the leading cause of hospitalizations for a 
LRTI during respiratory virus season. Premature infants with underdeveloped lungs 
and an immature immune system are particularly vulnerable to serious infections 
from RSV .1,2,4–6 The transmission of RSV is difficult to prevent because it is easily Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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transmitted by unprotected coughing or sneezing, or contact 
with contaminated hands.7 As many as 60% of all children 
are infected with RSV in their first year of life and almost 
100% within their second year of life.8 RSV does not stimu-
late a robust immunological response, therefore reinfection 
is common.9
Unfortunately, once children are infected with the virus, 
there are no etiopathogenetic treatment options available. 
Routine use of bronchodilators, epinephrine, steroids, and 
ribavirin has proven to be of no significant benefit; therefore, 
treatment has been limited to supportive measures.10
Palivizumab (Synagis®; MedImmune Inc, Gaithersburg, 
MD; marketed outside the USA by Abbott Laboratories, 
Abbott Park, IL) is a humanized IgG1 monoclonal antibody 
targeting the F protein of RSV. When administered monthly 
while RSV is circulating in the community, palivizumab 
has been shown to reduce severe RSV disease requiring 
hospitalization in high-risk children (ie, those born #35 
weeks gestational age; those with bronchopulmonary 
dysplasia; and infants with hemodynamically significant 
congenital heart disease who were less than two years of 
age at the start of RSV season), by approximately 50% 
compared to placebo.11,12 Approved in the United States in 
1998, palivizumab received European approval in 1999, 
and its approval in the Russian Federation was received in 
February 2010. Optimal timing of prophylaxis is based on 
epidemiological data.
A review of literature published over a 30-year period 
regarding RSV seasonality and epidemiology disclosed that 
RSV season in the northern hemisphere roughly starts in 
September and ends in April.5,6 European countries, including 
those countries near Russia, with published data, had similar 
RSV seasons that started as early as September, and ended as 
late as July.13–24 In the Nordic countries of Finland,   Denmark, 
Norway, and Sweden, RSV season begins in October or 
November and continues through March or April, with peak 
activity in December/January.5,18,25 In Norway, RSV has been 
reported through June, with later peak activity in January/
February.14 Although the Russian Federation covers a very 
large territory, including arctic areas and subtropics, most of 
its population occupies temperate regions.
The objective of this study was to describe the prevalence 
and seasonality of RSV infection in children aged #2 years, 
hospitalized for LRTI between September 2008 and April 
2009, in three temperate regions of the Russian Federation. 
Demographic information, morbidity, and risk factors are 
also reported.
Methods
This prospective, multicenter, observational study was con-
ducted at nine participating hospital centers located in three 
regions: seven in Moscow (Central), one in Saint Petersburg 
(Northwest), and one in Tomsk (East). The study included 
parental written informed consent and received approval from 
the Institutional Ethics Boards of all participating centers. The 
timing of the study, from September 2008 through April 2009, 
allowed essential epidemiological information on RSV to be 
obtained during the cold season in the northern hemisphere 
when RSV is most prevalent. The plan was to enroll approxi-
mately 500 eligible children into the study over the period.
study population
All children with LRTI hospitalized at participating centers 
were potentially eligible for enrollment. The determination of 
LRTI was based on a medical diagnosis of acute bronchiolitis, 
bronchitis, and/or pneumonia, and based on the presence of 
symptoms (cough, coryza, rhinorrhea, fever, or retractions) 
and signs (wheezing, crackles, or rales). Children with at 
least one symptom and a chest radiograph diagnostic of 
bronchiolitis, pneumonia, or bronchitis were also designated 
as having an LRTI. Additionally, apneic events with 
accompanying auscultatory findings, chest radiograph of 
LRTI, clinical symptoms of fever, or coryza were designated 
an LRTI episode.
Eligibility requirements also included age #2 years at 
the time of hospital admission and hospitalization ,24 hours 
prior to RSV testing. Enrollment was prohibited if the child 
had received any product containing RSV-neutralizing 
antibodies (including hyperimmunoglobulins) within 
100 days of enrollment, or had participated in a clinical 
trial for RSV treatment or prophylaxis prior to or during the 
hospitalization.
Procedures
Physical examination was performed and a parent provided 
information regarding the child’s personal and family medical 
and social history during a single screening and enrollment 
visit prior to RSV testing. The RSV diagnostic test method 
utilized was approved for use by regulatory authorities in the 
Russian Federation. Nasopharyngeal lavage was collected 
and evaluated within 24 hours of hospitalization, using a 
rapid immunochromatographic RSV detection technique, 
QuickStripe™ RSV (Savyon Diagnositics Ltd, Ashdod, 
Israel). Two retests could be conducted within 24 hours of 
enrollment if the initial test results were inconclusive.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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A classification of children at “high-risk” for serious RSV 
infection was made based on a medical history of premature 
birth (#35 weeks of gestational age); chronic lung disease 
(CLD), including bronchopulmonary dysplasia (BPD); or 
congenital heart disease (CHD). The details of hospital 
stay and discharge were recorded from the hospital medi-
cal records using study-specific case report forms only for 
RSV-positive (RSV+) children. No hospitalization data were 
recorded for RSV-negative (RSV-) children. No subsequent 
visits were required for any enrolled child and no interven-
tions were assessed in the study.
Data analysis
All children enrolled in the study formed the analysis 
population for primary and secondary analyses, irrespective 
of RSV diagnosis. The primary analysis, RSV prevalence, was 
determined by the number and proportion of RSV+ children 
(95% exact confidence interval [CI] for the proportion), 
calculated by dividing the total number of RSV+ children 
by the total number of children tested for RSV .
Seasonality was determined within the study period of 
September 2008 through April 2009. The number and pro-
portion of RSV+ children enrolled was calculated at weekly 
intervals and across the entire study period. Calculations were 
performed for the total enrollment overall and for children 
from each of the three individual geographic areas.
Characteristics were evaluated using descriptive 
statistics. Means and standard deviations were calculated 
for continuous variables. For categorical variables, the 
number and percentage of enrollees in each category within 
an assessment were calculated.
Length of hospital stay, use and duration of oxygen sup-
plementation, use of mechanical ventilation, use and duration 
of continuous positive airway pressure (CPAP), admission 
to an intensive care unit (ICU), duration of stay at ICU, and 
mortality were summarized descriptively. For continuous 
variables, comparisons of RSV+ children that were at “high 
risk” and “not at high risk” for serious RSV infection (based 
on medical history as described in Methods) were made using 
a one-way analysis of variance (ANOVA) with group as the 
only factor. For categorical variables, the number and percent-
age of children in each category within an assessment were 
calculated for non-missing data, and comparisons of RSV+ 
children that were at “high risk” and “not at high risk” for 
serious RSV infection were made using Fisher’s exact test. 
P-values were based on two-tailed tests. Tests resulting in a 
P value # 0.05 were considered statistically significant.
Risk and protective factors were descriptively compared 
between RSV+ and RSV- children. No statistical tests were 
performed on these comparisons.
Results
Enrollment
Screening and enrollment began on September 11, 2008 with 
four active centers. The number of centers increased gradually 
to nine by February 2009, and continued through to the end of 
enrollment on April 26, 2009. Three centers (two in Moscow 
and one in Tomsk) had two enrolling locations each.
Of 593 children aged #2 years assessed for inclusion 
in the study, 520 were enrolled. The primary reason for 
non inclusion was parental unwillingness to provide con-
sent. The withdrawal of consent occurred for one enrolled 
child prior to RSV testing. The total data set for this study 
comprised the remaining 519 children.
Table 1 summarizes the demographic characteristics 
of all children enrolled, of the RSV+ subset, and of high-
risk RSV+ individuals by location. Children with RSV+ 
were predominantly full-term, white, males, of an appropriate 
weight for gestational age, and 7.5 months of age, on average, 
at hospitalization. These characteristics were similar to those 
of the total set; however, the mean age at hospitalization in 
the RSV- subset was 9.7 months.
In physical examination conducted at enrollment, 
vital signs (mean ± SD) were similar among the subsets: 
respiratory rate (40.9 ± 10.60 breaths⋅min-1) and heart rate 
(130.5 ± 12.88 b⋅min-1), oxygen saturation (96.0 ± 2.60%), 
temperature (37.0 ± 0.58°C), length (68.9 ± 10.09 cm) and 
body weight (8.5 ± 2.69 kg).
Prevalence and seasonality of rsV
During the period of September 11, 2008 through April 26, 
2009, 197 of 519 children enrolled were RSV+ (38.0%, 95% 
CI: 33.8–42.3). The prevalence of RSV was highest in Mos-
cow, where 151 of 362 children enrolled were RSV+ (41.7%, 
95% CI: 36.6–47.0). In St. Petersburg, RSV was identified 
in 19 of 50 children enrolled (38.0%, 95% CI: 24.7–52.8), 
and 27 of 107 children enrolled were RSV+ (25.2%, 95% 
CI: 17.3–34.6) in Tomsk.
The onset of RSV occurred in Moscow during week 44 
(late October) of 2008 (Figure 1). Peak RSV activity occurred 
during week 14 of 2009 (early April), when 62% of children 
with LRTI enrolled were RSV+ (31/50, 95% CI: 47.2–75.4). 
During the following two weeks, at the end of the recruit-
ment phase, the proportion of RSV+ children among those Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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enrolled decreased to 39% (11/28, 95% CI: 21.5–59.4). The 
protocol-defined duration of the study did not allow for a 
determination of season offset.
Morbidity and mortality
Among high-risk RSV+ children, the length of hospital stay 
ranged from 4–13 days vs 1–37 days among RSV+ children 
without high-risk conditions. More of the RSV+ children at 
high risk for serious RSV infection required oxygen supple-
mentation than the other RSV+ children not at high risk 
(28% v 10%, P = 0.04). The maximum duration of oxygen 
supplementation was 7–10 days, irrespective of risk category. 
No mechanical ventilation, CPAP, or surgeries were required 
and there were no deaths.
risk and protective factors
Physiological risk factors have been described above. 
In addition to those already presented, family and social 
history factors were identified and are described in Table 2. 
In the RSV+ subset at high risk for serious RSV infection, 
14 children were born premature, two had a history of 
CHD, and two had a history of CLD/BPD. Two criteria 
were identified for one high-risk child with RSV+ who was 
born premature and had a history of BPD. Medical histories 
revealed one or more hospitalizations in the high-risk RSV+ 
subset (50%), compared with the RSV+ (25%) and RSV- 
(37%) subsets not at high risk. Similarly, in the high-risk 
RSV+ subset, 50% of the children had been admitted to an 
ICU at birth, compared with 4% in the RSV+ and 7% in the 
RSV- subsets not at high risk.
Discussion
The prevalence of RSV during the 2008–2009 season in 
the Russian Federation was consistent with that expected 
in a northern temperate zone. The peak of RSV activity 
occurred in March–April. Both the prevalence of RSV 
and the peak of RSV activity were similar in the three 
participating cities. An abnormally warm autumn and a 
late winter cold-weather onset were recorded in temperate 
regions of the Russian Federation during the 2008–2009 
season.26 This unexpected factor serves as a reminder that a 
single season may not be representative of the RSV season 
from year to year.
Table 1 Demographic characteristics at enrollment
All  
(N = 519)
RSV+  
(N = 197)
High-risk RSV+a
Moscow  
(N = 17)
St. Petersburg   
(N = 1)
Males (%)  330 (64) 120 (61) 10 (59) 1 (100)
White race (%) 505 (97) 195 (99)b 17 (100) 1 (100)
Age (months; 
mean ± sD)
8.8 ± 6.37 7.5 ± 5.86 8.6 ± 7.1 11.0 ± 0.0
Birth weight  
(kg; mean ± sD)
3.3 ± 0.61 3.4 ± 0.66 2.2 ± 0.7 2.1 ± 0.0
gestational  
age (weeks;  
mean ± sD) 
39.0 ± 2.2 38.9 ± 2.4 33.6 ± 3.7 32.0 ± 0.0
Multiple  
birth (%)
25 (5) 13 (7) 5 (29) 0 (0)
Notes: ano high-risk rsV+ children were enrolled in Tomsk. bTwo children were 
Asian. High-risk was defined as a medical history of at least one of the following 
conditions: premature birth (#35 weeks of gestational age); chronic lung disease/
bronchopulmonary dysplasia; or congenital heart disease. rsV+ diagnosis made by 
immunochromatographic testing of nasopharyngeal lavage.
Abbreviations: rsV+, respiratory syncytial virus positive; sD, standard deviation.
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Figure 1 rates of enrollment over the study period at weekly intervals and 
rsV prevalence overall and by city. The onset of the rsV season occurred in 
late October 2008 (week 44), and peak activity was observed between weeks 
10 and 17 of 2009 (March–April). in all locations, rsV+ enrollments increased 
dramatically in weeks 12 to 15 of 2009 (March–April), near the end of the period 
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Considering the variability reported in published 
epidemiological studies, the late arrival of the RSV peak was 
not exceptional. Russia may have an epidemiology similar to 
that of Finland, Sweden, and Norway, where later seasons are 
a regular occurrence not associated with the weather, and RSV 
peaks in March–April.18 Such variability is not only found in 
far north or northeastern European countries. In Croatia, RSV 
seasons have two-year cycles, with seasons occurring from 
October to April one year and from December to June the next 
year, and with corresponding peaks in December–January and 
March–May.13,21 In Ireland, RSV onset occurs in November and 
year-to-year, the RSV peaks vary in occurrence from December 
through February.27 The RSV peak reported in Germany appears 
to be dependent upon the timing of RSV season onset, such that 
when onset is in December, peak activity has been reported in 
March.22,23 In Italy, RSV onset occurs in December, peaks in 
March, and offsets in April.28,29 In Turkey, RSV peaks in March, 
with onset in September and offset in May.24
The prospective design of this study contributed to the gen-
eralizability of results. All children with LRTI hospitalized in the 
participating centers were regarded as potential candidates for the 
study; therefore, the study was designed to represent the general 
population and to evaluate the prevalence of risk factors for RSV+ 
LRTI. By design, demographic data, risk and protective factors, 
and other descriptive information of the study population were 
collected without bias before the RSV test was administered.
Demographic characteristics and risk factors for 
severe RSV infection identified in the Russian Federation 
were consistent with those in other developed countries where 
children most at risk are those born premature, with chronic 
lung disease, or with congenital heart disease.19,30 Risk factors 
for hospitalization, such as sex (male); low birth weight 
(,10th percentile); exposure to school-age children in the 
home; daycare attendance; failure to breast feed beyond two 
months; cigarette smoke exposure; crowded living conditions; 
chronologic age ,six months at the time of RSV exposure; 
and being underweight at birth,31,32 were also factors in the 
children with RSV+ LRTI. It is important to keep in mind that 
in previous studies, children born shortly before or during the 
RSV season were significantly more likely to be hospitalized 
for RSV+ LRTI than children born during other periods of the 
year.31,32 These implications are key in that children who are 
at the highest risk of infection and complications leading to 
hospitalization are those most in need of prophylaxis.
Limitations of the study that may have influenced the 
results include the sensitivity of the rapid immunochro-
matographic RSV detection method (70%–90%), leaving 
a potential 10%–30% margin of error in identifying RSV 
infections. Enrollments in St Petersburg and Tomsk were 
relatively low and each city had only one participating site, 
therefore the prevalence of RSV in those cities may not have 
been adequately captured. Additional studies would be needed 
to provide a more precise definition of the RSV season than 
those provided by data collected during a single season. 
Although it can be argued that such factors can be general-
izable for all regions of the Russian Federation as a whole, 
the epidemiological data collected in this study remain both 
valuable and important as they are consistent with what has 
been documented globally and in Europe concerning RSV .
This study confirms that RSV is widespread among 
populations in three major temperate regions of the Rus-
sian Federation and is a significant cause of LRTI leading 
to the hospitalization of young children. During one RSV 
“season”, September 2008 through April 2009, enough data 
were obtained to evaluate the burden and need for RSV 
prophylaxis in high-risk infants. Inclusion criteria ensured 
homogeneity of the population and objective, evidence-based 
medical diagnosis procedures were adequate to support a 
conclusion regarding the disease prevalence and seasonality. 
All of these factors contribute to the generalizability of the 
results for the purposes intended; specifically, the preparation 
of health facilities to meet the burden of care and the effective 
timing of RSV prophylaxis with palivizumab.
Conclusion
RSV was a major contributor to LRTI hospitalization in the 
Russian Federation from October 2008 through April 2009. 
Table 2 Prevalence of risk factors among rsV+ and rsV- children
RSV+  
(N = 197)
RSV- 
(N = 322)
Mother smoked tobacco 
during pregnancy (%)
28 (14) 66 (21)
Passive cigarette smoke 
exposure in home (%)
90 (46) 186 (58)
number of siblings in  
the home (mean ± sD) 
0.8 ± 0.75 0.7 ± 0.70
Age of youngest sibling in  
the home (years; mean ± sD)
4.0 ± 2.62 4.4 ± 2.84
number of people living  
in the home (mean ± sD)
3.4 ± 1.19 3.5 ± 1.42
Daycare attendance (%) 4 (2) 12 (4)
number of furred pets  
inside home (mean ± sD)
0.4 ± 0.68 0.5 ± 0.73
Family history of atopy (%) 38 (19) 69 (21)
Months breastfed (mean ± sD) 4.6 ± 4.68 4.9 ± 4.50
Note:  rsV+/rsV-  diagnosis  made  by  immunochromatographic  testing  of 
nasopharyngeal lavage.
Abbreviations:  rsV+,  respiratory  syncytial  virus  positive;  rsV-,  respiratory 
syncytial virus negative; sD, standard deviation.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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Its prevalence among hospitalized children #two years of 
age was consistent with that in other developed countries. 
The 2008–2009 RSV season in the Russian Federation had 
an onset similar to other northern temperate zones. Although 
the period of peak activity occurred in March–April, later 
than previously reported in temperate regions of the northern 
hemisphere (December–January), it was not exceptional or 
inconsistent with ranges reported overall. The seasonality of 
RSV was similar with respect to onset and peak RSV activity 
between each of the three participating cities (regions). The 
demographics and risk factors identified among children 
hospitalized with RSV were similar to those described outside 
of the Russian Federation. These data support the consider-
ation of an effective time period for RSV control measures, 
including RSV prophylaxis in children at high risk for serious 
RSV infection requiring hospitalization.
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